Condition: Non-Small Cell Lung Cancer · EGFR Exon 20 Insertion Mutation · Sponsor: BeBetter Med Inc
This study is an open-label, multicenter Phase II trial, planning to enroll 200 subjects, using BEBT-109 capsules as monotherapy, aimed at evaluating the efficacy and safety of BEBT-109 capsules in subjects with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in locally advanced or metastatic Non-Small Cell Lung Cancer （NSCLC）.
This description comes directly from the study's public registry record.
Kegang Jiang, Master · +86-18664786382 · kjiang@bebettermed.com
Always discuss trial participation with your own doctor first.
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06706713